AU723500B2 - Caffeine composition as medicament and use thereof - Google Patents

Description

WO 96/32952 PCTINZ96/00032 -1- Caffeine composition as medicament and use thereof TECHNICAL FIELD The present invention relates to a medicament for treating humans for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated.

BACKGROUND ART In my US Patent Specification No.5275828, the full contents of which are hereby here included by way of reference, there is disclosed and claimed a medicament comprising an effective amount of a mixture of potassium iodide, ammonium chloride and caffeine for treating viral infections and bacterial infections commonly associated therewith. In particular there is disclosure of the use of such a composition for treating equine viral infections and bacterial infections commonly associated therewith.

A preferred medicament disclosed and claimed in the aforementioned specification comprised potassium iodide 200 mg/L to 800 mg/L ammonium chloride 200 mg/L to about 800 mg/L, and caffeine 200 mg/L to about 800 mg/L.

A particularly preferred medicament of the aforementioned US Patent specification 5275828 additionally included aqueous chloroform 10 ml/L to about 40 ml/L.

There is also disclosure of administration of such a composition in an amount between about 30 ml and 120 ml on a daily basis.

The medicament of my US Patent specification 5275828 was applied both to unhealthy and well as healthy horses.

Encouraged by the success of a medicament as disclosed in US patent specification 5275828 in respect of the treatment of horses as well as other animals such as cats, dogs, calves and humans, I have now turned to formulating a form of the medicament suitable for use with humans.

DISCLOSURE OF INVENTION Accordingly in a first aspect the present invention may broadly be said to consist WO 96/32952 PCT/NZ96/00032 in a medicament comprising or including Caffeine (Anhydrous) about 2.0g/100ml Potassium Iodide about 2.0g/100ml and Ammonium Chloride about 2.0g/100ml.

In a preferred form of the present invention the medicament comprises or includes Caffeine (Anhydrous) about 2.0g/100ml Potassium Iodide about 2.0g/100ml Ammonium Chloride about 2.0g/100ml Methyl Paraben about 100mg/100ml and Isopropyl Paraben about 50mg/100ml.

In a preferred form of the present invention the medicament comprises Caffeine (Anhydrous) about 2.0g/100ml Potassium Iodide about 2.0g/100ml Ammonium Chloride about 2.0g/100ml Methyl Paraben about 100mg/100ml Isopropyl Paraben about 50mg/100ml Glycuol BP about 12.5g/100ml Syrupus BP about 40g/100ml Alcohol WS 95 about 5.7g/100ml Green No.5 1% soln about 0.5g/100ml In a further aspect the present invention consists in a medicament suitable for the treatment of mammals for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for the use as a detoxicant mixture with any such mammal, said medicament comprising or including Caffeine (anhydrous) about Potassium Iodide about 20g/L, and Ammonium chloride about Preferably said medicament also includes: Methyl paraben and isopropyl paraben together with compatible carriers and orally acceptable inclusions.

In yet a further aspect the present invention consists in a method of treating a human or mammal for viral infections and/or bacterial infections commonly associated WO 96/32952 PCT/NZ96/00032 -3therewith and/or for ailments where detoxification might be indicated and/or for detoxifying such a mammal, said method comprising the steps of periodically administering or having administered to such a mammalian patient an effective amount of a medicament comprising caffeine (anhydrous) about 20g/L, potassium iodide about 20g/L and ammonium chloride about Preferably said medicament also includes methyl paraben and isopropyl paraben together with optionally compatible carriers and orally acceptable inclusions.

Preferably in the case of a human, a daily optimum dosage of about lml/6Kg of body weight is administered daily after a lead up period of lower dosing.

DETAILED DESCRIPTION OF THE INVENTION Table 1

HUMAN

PROBLEM DOSE/ RESULT SIDE EFFECTS APPROXIMATE PATIENT SEX DAY DURING DURATION OF AGE TREATMENT TREATMENT (YEARS)

(MONTHS)

Bronchitis 1Omis No Bronchitis Runny Nose, 3 Months 52 F No Chest Pain Phlegm, Weight Increase Blood 10mls No Headaches 1 Month 47 M Pressure Decreased Headaches Blood Pressure to Normal Nausea, 1Omls Lost all of 1 Month 40 M Headaches, Problems Cough Lethargy Bad Hearing 2mls Normal Runny Nose, 1 Months 4/ M Glue Ear Hearing Mucus Mucus Cleared Wheezing, 3mls Easy Breathing 1 Month 7 M Bad at Breathing, Asthma WO 96/32952 PCT/NZ96/00032 Emphysema 10mls Much Pimples on Head I Month 63 M (lungs) Improved and Back Breathing, Side Effects Cleared Short of 10mIs Clear lungs 3 Months 49 M Breath, Sores Emphysema, Psoriasis Asthma 15rals Good Mucus, Nasal 4 Months 47 M Using Breathing No Discharge Inhailer need for inhaler Tiredness, variable All Problems Nasal Discharge, 2 Months F Asthma Gone Pimples Asthma 1 Omls Improved Weight Loss 2 Months 44 F Bronchial 10mis Improved Does Nasal Discharge 4 Months 77 F Asthma Not Use Inhaler Anymore Herpes on I Orals No Herpes nor Nasal Discharge, 11/2 Months. Still 52 M Lips, Flu, Brucellosis Pimples on Back, healthy after 3 Headaches Muscle Weakness years from time of treatment Flu, 30mls Sleep Better, Runny Nose 2 Months 36 F Headaches No Problems, Quick Recovery from Flu Tired 3Omls Feel Better Constipated 1 Month 58 F Flu 1ltnis Quick Runny Nose 2 Months 42 M Recovery Runny 5mls All Problems 1 Month 8 M Nose/Cough Gone Runny 5mls All Problems 1 Month 35 M Nose/Cough Gone Flu Omls All Problems I Month 17 F Gone WO 96/32952 PCT/NZ96/00032 Cold Sores 10mIs Less Tired, Rash on Back 2 Months 27 F More Energy Shingles 5 10mls Problem Gone 5 Months 66 M Shingles, 10mls More Energy, 3 Months 65 M Sores Rashes Gone Tiredness, lOmIls Rashes Gone, Pimple Outbreak 3 Months 36 F Psoriases, No Coldsores Headaches or Headaches SLE ISmis Energy This is a medical 12 Months 38 M Increase and riddle. Now felt better healthy.

ME CFS 10- Energy Discharge from Continuing. Now 28 M PUS 15mls Increase, Much Nose 98% cured on golf Improved cours 5 days a week.

Jaundice, 15mIls Impotence Nasal Discharge 2 Months 56 M Sore Joints, Cured, No Tiredness Pain, Energy Increase Bronchitis 10- Much Continuing 59 F 12mls Improved Lead 1omls Feeling Better Aching Stomach 3 Months 39 F Poisoning/ Fibroid gone Muscles Menopause Prostate lOMs Normal 11 Months 78 M Gland Urination, Malfunction Energy Increase Chronic 5mls Sinus Cleared, 2 Months 52 F Sinus Sleeping Better Problem for Years Hepatitis C 15mls Help Nausea, Sweats 2 Months 39 M Eczema 5mls All Areas 2 Months 9 F about Mouth, Almost Chest and Cleared Back I II WO 96/32952 PCT/NZ96/00032 Y Y Y Lymphatic Cancer lOmls Haemoglobin rose from 12.4 to 15.9 [normal is 12 to 18] and white cells dropped from 9.7 to 5.6 [normal is 4 to 11] Had had maximum chemotherapy.

3 years since treatment feels 100% 3 Months Prostate lOmls Prostate Feels better. 22 Months 74 M Cancer specific antigen lowered from 37.6 to 0.9 [normal is 0 to 4] Diabetes lOmls sSugar level Feels better and 5 Months 74 M dropped from more energetic.

13.1 to [normal is 5 to 8] The composition of the present invention was taken by human subjects on a daily basis. Each subject administered or was administered a prescribed daily dose over various periods, for the treatment of their infection. Subjects were requested to provide their background information and keep a record of the results of treatment.

Various symptoms of viral diseases were displayed by the subjects prior to treatment and included various skin disorders, Asthma, Bronchitis, Flu Colds including general tiredness and other flu symptoms, and emphysema to name a few. Although subjects were subjected to differing doses and differing durations of treatment most subjects showed a marked improvement by a diminishing if no complete clearing of symptoms.

Several subjects had previously been treated with other types of medication or methods of treatment without much success. Treatment with the composition of the WO 96/32952 PCT/NZ96/00032 -7instant invention rapidly obviated symptoms displayed by most subjects, and most subjects no longer needed to rely on previous medication. As an example one subject suffering from Asthma stated that he no longer used his inhaler.

During the initial stages of treatment, several subjects had at least one side effect.

The most common side effect displayed by subjects was a nasal discharge. Other side effects include acne out breaks on the back and on the head or phlegm and mucus discharges.

In most circumstances such side effects lasted a short period after which both the symptoms of the side effect and the original symptoms disappeared.

The dosage administered to subjects varied depending on symptoms and subject age. The age of the group of subjects varied from 4 years to 78 years.

Several of the records provided from subjects were completed by medical doctors, which provided a more expert opinion on the symptoms, side effects and results.

The mixture was administered to human subjects on a daily basis. Each subject administered a prescribed daily dose to themselves over various periods, for the treatment of their infection. Subjects were requested to provide their background information and results of treatment.

The various symptoms displayed by the subjects prior to treatment included various skin disorders, Asthma, Bronchitis, Flue and colds including general tiredness and other flu type symptoms, emphysema, prostrate cancer, diabetes to name a few. Although subjects were subjected to differing durations of treatment, most subjects showed a marked improvement by a diminishing if not complete clearing of symptoms.

Several subjects had been treated with other types of medication or methods of treatment without much success. Treatment with the composition of the instant invention rapidly obviated symptoms displayed by most subjects, and most subjects did not need to rely on other earlier used medication. One subject suffering from Asthma stated that he no longer used his inhaler. Although during the initial stages of treatment, several subjects had at least one side effect. The most common side effect displayed by subjects was a nasal discharge. Other side effects include acme outbreaks on the body and on the head or phlegm and mucus discharges. In most circumstances such side effects lasted a short period after which both the symptoms of the side effect and the original symptoms WO 96/32952 PCTINZ96/00032 -8disappeared.

The dosage administered to subjects varied depending on symptoms and subject age. The age of the group of subjects ranged from 4V 2 to 78 years.

Several of the records provided from subjects were completed by medical doctors.

5 The most preferred form of the present invention for human usage is a composition as follows: Caffeine (Anhydrous) about 2.0g/100ml Potassium Iodide about 2.0g/100ml Ammonium Chloride about 2.0g/100ml Methyl Paraben about 100mg/100ml Isopropyl Paraben about 50mg/100ml Glycuol BP about 12.5g/100ml Syrupus BP about 40g/100ml Alcohol WS 95 about 5.7g/100ml, and Green No.5 1% soln about 0.5g/100ml.

The composition has the following physical characteristic green solution with viscosity slightly greater than water.

Recommended optimum daily dosage is lml/6Kg body weight per Kg of patient.

Initial dosages are to extent tolerated by patient with gradual (preferably weekly) increase to the optimum level. A suggested start may be as low as 2mls per patient.

Claims (9)

1. A medicament comprising or including 9 5 Caffeine (Anhydrous) Potassium Iodide Ammonium Chloride

2. A medicament of claim Caffeine (Anhydrous) Potassium Iodide Ammonium Chloride Methyl Paraben Isopropyl Paraben

3. A medicament of claim Caffeine (Anhydrous) Potassium Iodide Ammonium Chloride Methyl Paraben Isopropyl Paraben Glycuol BP Syrupus BP Alcohol WS 95 Green No.5 1% soln about 2.0g/100ml about 2.0g/100ml and about 2.0g/100ml. 1 which comprises or includes about 2.0g/100ml about 2.0g/100ml about 2.0g/100ml about 100mg/100ml and about 50mg/100ml. 1 which comprises or includes about 2.0g/100ml about 2.0g/100ml about 2.0g/100ml about 100mg/100ml about 50mg/100ml about 12.5g/100ml about 40g/100ml about 5.7g/100ml about 0.5g/100ml

4. A medicament suitable for the treatment of mammals for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for the use as a detoxicant mixture with any such mammal, said medicament comprising or including Caffeine (Anhydrous) about Potassium Iodide about 20g/L and Ammonium Chloride about A medicament of claim 4 which also includes: methyl paraben and isopropyl paraben together with compatible carriers and orally acceptable inclusions.

WO 96/32952 PCT/NZ96/00032

6. A method of treating a human or mammal for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for detoxifying such a mammal, said method comprising the steps of periodically administering or having administered to such a mammalian patient an effective amount of a medicament(s) comprising caffeine (anhydrous) about potassium iodide about 20g/L and ammonium chloride about

7. A method of claim 6 wherein said medicament(s) also includes or include methyl paraben and isopropyl paraben together with optionally compatible carriers and orally acceptable inclusions.

8. A method of claim 6 or 7 wherein daily optimum dosages of the medicament(s) is or are administered only after a lead up period of lower dosing.

9. A method of claim 6, 7 or 8 wherein for a human patient a daily optimum dosage of about lml/6Kg of body weight is administered daily after a lead up period of lower dosing.